Stock Decline – Talk Bio

Compass Pathways Achieves Phase 3 Win for Psilocybin in Depression, Yet Stock Tumbles

1 week ago talkbio0Tagged Clinical Trials, COMP360, Compass Pathways, Investor Reaction, Mental Depression, Psilocybin, Stock Decline, treatment-resistant depression, United States Food and Drug Administration

Compass Pathways; COMP360; psilocybin; Phase 3 trial; depression; treatment-resistant depression; clinical trial; stock decline; investor reaction; FDA

Analysts Downplay Intellia Adverse Event, but Gene Therapy Safety Remains Under Scrutiny

1 month ago talkbio0Tagged Adverse event, ATTR-CM, Event, Gene Modification, gene therapy, Intellia, liver transaminase, MAGNITUDE trial, Response process, Safety, Stock Decline

Intellia Therapeutics; gene therapy; safety event; adverse event; MAGNITUDE trial; liver transaminase; stock decline; ATTR-CM; gene editing; analyst response

Fortrea CEO Steps Down Amid Continued Stock Decline Post-Labcorp Spinout

2 months ago talkbio0Tagged CEO, Clinical Trials, CRO, departure - ActRelationshipType, Fortrea, Labcorp, Leadership Change, public company, Stock Decline

Fortrea; Labcorp; CEO departure; stock decline; CRO spinout; leadership change; clinical trials; public company